content ed net

GLOBAL SITE

Published Articles

List of published articles

  • Long-Term Safety and Clinical Outcomes of Motugivatrep (SJP-0132) 0.3% Ophthalmic Suspension in Patients with Dry Eye Disease: An Open-Label, Phase 3 Study

    Source: Clinical Ophthalmology
    DOI: https://doi.org/10.2147/OPTH.S626385

  • Motugivatrep (SJP-0132) 0.3% Ophthalmic Suspension for Dry Eye Disease: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Trial

    Source: Clinical Ophthalmology
    DOI: https://doi.org/10.2147/OPTH.S615529

  • Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1/2 Study of a TRPV1 antagonist SJP-0132 in Participants with Dry Eye Disease

    Source: American Journal of Ophthalmology
    DOI: https://www.ajo.com/article/S0002-9394(26)00016-4/abstract

  • Efficacy and Safety of SJP-0132 in Patients with Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study

    Source: American Journal of Ophthalmology
    DOI: https://doi.org/10.1016/j.ajo.2025.11.036

  • 1